The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...

From medical neglect to suicide, the lack of information on jail deaths can allow the same deadly problems to lead to more ...

Between 2021 and 2023, COVID-19 dropped from the world’s leading cause of death to the 20th, while life expectancy surpassed ...

In an article published in The Lancet HIV, authors including Distinguished Professor Denis Nash and Professor Constantin Yiannoutsos aim to provide the most comprehensive estimates of pediatric ...

Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? Here's what you'll learn when reading this story: The challenge with curing the Human ...

Introduction: Human immunodeficiency virus (HIV), syphilis, and hepatitis B virus (HBV) infection pose a major global public health challenge. However, high-quality integrated data on the burden of ...

Merck (NYSE:MRK) reported positive results from late-stage studies on a new oral treatment which combines two drugs, doravirine and islatravir, for adults with HIV-1. The studies looked at adults ...

Scientists at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter have received $15.7 million in four separate federal grants to help with their research over ...